Project Grant R01CA289624
Award Date
7/18/24
Completion Date
6/30/29
Dollars Obligated
$1.8M
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This $3,510,000 five-year Project Grant award under the National Cancer Institute's Cancer Biology Research (CFDA 93.396) program supports research by the Sanford Burnham Prebys Medical Discovery Institute to investigate the effects of aging on melanoma metastasis mechanisms. The research aims to define how key components of the unfolded protein response (UPR), such as the transcription factor ATF4, impact pro- and anti-apoptotic signaling in melanoma under conditions of aging. The project...
The National Cancer Institute (NCI) awarded a $1,510,463 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to conduct research on the regulation of tumor-associated immune macrophages (TAMs) and their metabolic properties. The project aims to elucidate how the composition and activity of the mitochondrial electron transport chain complex IV in TAMs are controlled...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $227,906 to The Trustees of the University of Pennsylvania to develop a first-of-its-kind technology for spatially resolved co-mapping of epigenome, transcriptome, and proteins in formalin-fixed paraffin-embedded (FFPE) tissue samples at the cellular level. The goal is to advance the understanding of intratumoral heterogeneity and the complex interactions between cancer and surrounding...
The National Cancer Institute (NCI) awarded a $499,626 Project Grant under the Cancer Biology Research (CFDA 93.396) program to The Wistar Institute of Anatomy and Biology, a non-profit biomedical research institute in Philadelphia. The five-year grant, awarded on August 5, 2024, will fund research to elucidate how the PARKIN tumor suppressor protein functions to activate antitumor immune responses and inhibit tumor growth and metastasis. The research will characterize how PARKIN...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,971,618.00 to The Trustees of the University of Pennsylvania to develop engineered extracellular vesicles (EVs) derived from natural killer (NK) cells as an effective cell-free immunotherapy for solid cancers like melanoma. The key products/services being delivered include: Optimizing the cytotoxicity and immune-stimulatory functions of DR5-scFv EVs, which target the death...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $312,892 to Duke University to investigate the role of type 3 innate lymphoid cells (ILC3s) in modulating the melanoma tumor microenvironment. The research aims to better understand how ILC3s, which can create immunosuppressive environments, impact the effectiveness of immune checkpoint inhibitor (ICI) therapy in treating advanced melanoma. By more precisely defining...
This Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) provides $395,509 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct research on targeting the SKP2 protein pathway for anti-melanoma therapy. The key objectives are to: 1) define the molecular mechanisms by which the dysregulated RNF12-SKP2 E3 ligase cascade promotes melanoma tumorigenesis, and 2) investigate how SKP2-mediated degradation of the HHIP protein plays an...
This $673,526 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will support research by the University of Pittsburgh to investigate the role of zinc metabolism in therapy-resistant melanoma. The research aims to 1) elucidate how the loss of the p16 tumor suppressor gene affects zinc transporter SLC39A9 expression and zinc homeostasis, and 2) determine how altered zinc levels in the tumor microenvironment impact CD8 T cell function and...
This R01 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $635,946 to Dartmouth-Hitchcock Clinic, a non-profit healthcare and research organization, to conduct a study examining the effects of ultraviolet B (UVB) radiation on melanoma progression and treatment response. The key objectives are to: 1) Test the hypothesis that UVB-induced interferon-I (IFN-I) elicits a melanocyte PD-L1-dependent inflammatory memory that promotes melanoma...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $442,236 in funding to the University of Alabama at Birmingham (UAB) over a period of 5 years, from January 1, 2025 to December 31, 2029. The goal of this research project is to determine the role of the YTHDF1 RNA-binding protein in driving melanoma metastasis through two key pathways: 1) anoikis resistance (cell-intrinsic) and 2) suppression of NK cell-mediated anti-tumor...